Free Trial
NASDAQ:SEEL

Seelos Therapeutics (SEEL) Stock Price, News & Analysis

Seelos Therapeutics logo

About Seelos Therapeutics Stock (NASDAQ:SEEL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2 shs
Average Volume
174,745 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Receive SEEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SEEL Stock News Headlines

Seelos Therapeutics, Inc. (SEELQ)
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
Seelos Therapeutics Inc SEELQ
Seelos gets Nasdaq delisting notice
See More Headlines

SEEL Stock Analysis - Frequently Asked Questions

Seelos Therapeutics shares reverse split on Friday, September 27th 2024. The 1-16 reverse split was announced on Wednesday, September 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Seelos Therapeutics investors own include Digital Turbine (APPS), Okta (OKTA), CrowdStrike (CRWD), SoFi Technologies (SOFI) and ChargePoint (CHPT).

Company Calendar

Today
4/24/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SEEL
Employees
20
Year Founded
2016

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,880,000.00
Pretax Margin
203.13%

Debt

Sales & Book Value

Annual Sales
$2.20 million
Price / Cash Flow
N/A
Book Value
($437.92) per share
Price / Book
N/A

Miscellaneous

Free Float
368,000
Optionable
Optionable
Beta
1.94

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:SEEL) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners